Amgen Aranesp oncology indication
This article was originally published in Pharmaceutical Approvals Monthly
Amgen's Aranesp is approved July 19 "for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy." The BLA was submitted Sept. 19, 2001, and was based on a 12-week, 314-patient trial. Updated labeling contains an emphasis on the less frequent dosing of darbepoetin alfa compared to epoetin alfa (Amgen's Epogen, J&J's Procrit). Amgen will detail the product with its oncology products Neupogen (filgrastim) and Neulasta (pegfilgrastim
You may also be interested in...
Notified bodies’ efforts to enhance a harmonized approach to remote audits have failed, raising questions about whether there is any avenue left to get vital devices certified by the 26 May EU MDR deadline.
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.